Detalhe da pesquisa
1.
SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model.
Arterioscler Thromb Vasc Biol
; 28(4): 665-71, 2008 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-18202322
2.
Evaluating glycemic control for patient-aligned care team clinical pharmacy specialists at a large Veterans Affairs medical center.
Pharm Pract (Granada)
; 16(2): 1164, 2018.
Artigo
Inglês
| MEDLINE | ID: mdl-30023024
3.
Adopting a practical statistical approach for evaluating assay agreement in drug discovery.
J Biomol Screen
; 10(5): 508-16, 2005 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-16093560
4.
Evaluating glycemic control for patient-aligned care team clinical pharmacy specialists at a large Veterans Affairs medical center
Pharm. pract. (Granada, Internet)
; 16(2): 0-0, abr.-jun. 2018. tab, graf
Artigo
Inglês
| IBECS (Espanha) | ID: ibc-174787
5.
Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI).
Bioorg Med Chem Lett
; 13(24): 4355-9, 2003 Dec 15.
Artigo
Inglês
| MEDLINE | ID: mdl-14643325